Tag:

Joe Jimenez

Latest Headlines

Latest Headlines

Will Novartis follow through with Gen-Probe bid?

Novartis CEO Joe Jimenez (photo) said last week that one prime dealmaking area for his company might be diagnostics. Along with potential buys in animal health, generics, biotech and consumer health,

Novartis scouts bolt-on deals of up to $3B

Novartis is scouting around for bolt-on deals. CEO Joe Jimenez (photo) says the Swiss company would spend up to $3 billion on consumer health and veterinary medicine acquisitions to beef up its

Novartis dismisses senior staffers for misconduct

When CEO Joe Jimenez (photo) went on an international tour of Novartis facilities, he ran across some behavior he didn't like. So, the company has fired several managers for ethical misconduct--and

Novartis CEO outlines a winning drug development strategy

Novartis ($NVS) CEO Joe Jimenez took a minute during a recent interview with Fortune to explain the company's drug development strategy. Rather than go after a blockbuster indication, Novartis

Novartis chief continues cost-cutting drive

Novartis ($NVS) chief Joe Jimenez (photo) started slashing expenses at the drugmaker even before he took over the CEO's job. That cost-cutting has continued apace, with jobs and facilities facing the

Novartis CEO vowing to back ambitious $8B R&D strategy

While Pfizer goes about the business of dramatically reducing its R&D budget, Novartis CEO Joe Jimenez says he isn't about to go down that path. Instead, says the CEO, he intends to snip away at

Novartis chief eyes bolt-on deals up to $1B

Novartis ($NVS) CEO Joe Jimenez (photo) has a shopping list, and he's not afraid to share it. At the World Economic Forum in Davos, Jimenez chatted about his appetite for deals with the Wall Street

Jiminez: Novartis ($NVS) isn't 'giving up' on pharma model

Call it the Swiss strategy squabble. In advance of his first big public show since taking over Novartis ($NVS) as chief executive, Joe Jiminez (photo) talked strategy with the Financial Times--and

Has pharma outgrown the scientist CEO?

Is the era of the scientist-CEO over in Big Pharma? The Financial Times suggests it's so. And to hear the experts tell it, there's a reason for that. Executives with lots of commercial and marketing

Novartis CEO goes on a 'decluttering' drive

New Novartis (NYSE:NVS) chief Joe Jiminez (photo) is talking execution again. In an interview with the Financial Times, Jiminez described some of his initiatives--and they're all about the E word.